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Abstract 
Background: Generalized anxiety disorder (GAD) is a common and highly comorbid 
anxiety disorder characterized by repetitive negative thinking (RNT). Treatment trials tend to 
exclude individuals with non-primary GAD, despite this being a common presentation in real 
world clinics. RNT is also associated with multiple emotional disorders, suggesting that it 
should be targeted regardless of the primary disorder. This study evaluated the acceptability 
and effectiveness of brief group metacognitive therapy (MCT) for primary or non-primary 
GAD within a community clinic. Methods: Patients referred to a specialist community clinic 
attended six, two-hour weekly sessions plus a one-month follow-up (N=52). Measures of 
metacognitive beliefs, RNT, symptoms, positive and negative affect, and quality of life were 
completed at the first, last, and follow-up sessions. Results: Attrition was low and large 
intent-to-treat effects were observed on most outcomes, particularly for negative 
metacognitive beliefs and RNT. Treatment gains increased further to follow-up.  
Benchmarking comparisons demonstrated that outcomes compared favorably to longer 
disorder-specific protocols for primary GAD. Limitations: No control group or independent 
assessment of protocol adherence. Conclusions: Brief metacognitive therapy is an acceptable 
and powerful treatment for patients with primary or non-primary GAD. 
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Introduction 
Generalized anxiety disorder (GAD) is one of the most common and highly comorbid 
anxiety disorders (Kessler, Chiu, Demler, & Walters, 2005; McEvoy, Grove, & Slade, 2011). 
Comorbidity with major depressive disorder is particularly high, with estimates up to 67% 
(Judd et al., 1998). Despite comorbidity being the norm rather than the exception in clinical 
practice (Brown, Campbell, Lehman, Grisham, & Mancill, 2001), most trials of evidence-
based treatments restrict clinical samples to individuals with a specific primary disorder. One 
potential obstacle to the dissemination of evidence-based treatments is the perception that real 
world samples are not reflected within treatment trials (Barlow, Levitt, & Bufka, 1999). 
Effectiveness research plays a critical role in demonstrating that efficacious treatments 
evaluated within research settings are transportable to settings with (a) highly complex and 
comorbid patients who are referred via clinical routes, (b) clinicians with diverse caseloads, 
and (c) where strict exclusion criteria are not applied and treatments are not closely 
monitored (Shadish, Matt, Navarro, & Phillips, 2000). Meta-analyses investigating the 
effectiveness of treatments under real world conditions have supported the proposition that 
efficacious protocols can be highly effective outside of research trials (Stewart & Chambless, 
2009). However, recent evidence suggests that more real world effectiveness trials are needed 
before clinicians are likely to perceive efficacy trials as being useful for guiding their clinical 
interventions (Gyani, Shafran, Myles, & Rose, 2014). This study contributes to the 
effectiveness literature by evaluating a brief group intervention targeting repetitive negative 
thinking (RNT) in primary and non-primary GAD within a community mental health clinic. 
RNT can be defined as cognitive perseveration on negative themes, with worry and 
rumination being the most commonly studied forms within the GAD and depression 
literatures, respectively. Worry has been defined as “a chain of thoughts and images, 
negatively affect-laden, and relatively uncontrollable” (Borkovec, Robinson, Pruzinsky, & 
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DePree, 1983), and rumination has been defined as “behavior and thoughts that focus one’s 
attention on one’s depressive symptoms and on the implications of the symptoms” (Nolen-
Hoeksema, 1991, p. 569). Wells and Matthews’ (1996) Self-Regulatory Executive Function 
(S-REF) model is a metacognitive account of emotional disorders, which suggests that 
positive beliefs about RNT (e.g., RNT is helpful) motivate an individual to engage more fully 
in RNT. Once RNT is commenced, negative beliefs about RNT (e.g., RNT is dangerous and 
uncontrollable) then lead to a range of counterproductive cognitive (e.g., suppression, threat 
monitoring) and behavioral (e.g., avoidance, alcohol use) changes which, in turn, lead to an 
escalation of RNT. This escalation of RNT strengthens negative beliefs about the 
uncontrollability and dangerousness of thoughts and, continuing the cycle, leads individuals 
to abandon functional attempts to reduce their engagement in RNT and instead to use more 
extreme and dysfunctional overcontrol strategies. Wells (2013) argues that negative beliefs 
about RNT have the “…most pervasive and powerful influences in psychological 
disorder…giving rise to a sense of acute danger, hopelessness, and inefficacy (p. 188-189).” 
Within the S-REF model, RNT, attentional bias toward threat, and problematic behaviours 
that exacerbate psychological distress are together referred to as the Cognitive Affective 
Syndrome (CAS). Whereas more traditional cognitive behavior therapy targets the content of 
negative automatic thoughts, MCT targets positive and negative metacognitive beliefs that 
maintain the CAS. 
Four MCT treatment trials for primary GAD have demonstrated large reductions in 
metacognitive beliefs and RNT. Two preliminary studies demonstrated promising effects, but 
small samples (Ns = 10) raise questions about the generalizability of the findings (Wells et 
al., 2010; Wells & King, 2006). van der Heiden, Muris, and van der Molen (2012) conducted 
a randomized controlled trial (RCT, N = 126) for primary GAD and found that 14 sessions of 
individual MCT was superior to intolerance of uncertainty therapy (IUT) and a delayed 
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treatment control (DT). van der Heiden, Melchior, and de Stigter (2013) subsequently 
evaluated 14 sessions of group MCT for primary GAD (N = 33), but found higher dropout 
(27% vs. 11%) and poorer outcomes than van der Heiden et al.’s (2012) trial of individual 
MCT. The authors concluded that group MCT might be less effective and acceptable than 
individual MCT, possibly due to there being less time to challenge each individual’s 
idiosyncratic metacognitive beliefs. It is notable that van der Heiden et al.’s (2013) groups 
were relatively large (10-14 patients/group), which represents a considerable efficiency over 
individual treatment. However, the large group sizes may have diluted treatment effects and 
contributed to the high attrition. The only other group MCT trial included just eight adults 
with obsessive compulsive disorder (Rees & van Koesveld, 2008), suggesting that more 
research is required to more fully evaluate the utility of group MCT. 
An important question that remains to be answered is whether these treatment effects 
would generalize to clinical samples with primary or non-primary GAD. The S-REF model, 
from which MCT derives, is a transdiagnostic theory (Wells & Matthews, 1996). MCT 
should therefore effectively reduce RNT regardless of the specific content of negative 
thoughts or primary diagnosis. Indeed, theory and accumulating evidence causally implicate 
RNT in the maintenance of various emotional disorders (Harvey, Watkins, Mansell, & 
Shafran, 2004; McEvoy & Brans, 2013; Nolen-Hoeksema & Watkins, 2011), and there is 
evidence that MCT is effective for a range of primary emotional disorders in addition to 
GAD, such as depression (Dammen, Papageorgiou, and Wells, in press; Papageorgiou & 
Wells, in press; Wells et al., 2012), social anxiety disorder (McEvoy, Mahoney, Perini, & 
Kingsep, 2009), and obsessive compulsive disorder (Rees & van Koesveld, 2008). 
Interventions targeting RNT may therefore be effective regardless of whether GAD is 
primary or not. No previous study has evaluated group-based MCT in a sample with primary 
or non-primary GAD. Given that comorbidity is the norm in clinical practice (Brown et al., 
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2001), and it may be impractical in many settings to run diagnosis-specific groups based on 
primary disorders, demonstrating that group MCT is effective in comorbid mixed-diagnosis 
populations is important for real world practice.  
The aim of this study was to evaluate the acceptability and effectiveness of brief MCT 
targeting RNT for individuals with GAD, regardless of whether or not GAD was their 
primary disorder. This study met several criteria for an effectiveness trial, including clinically 
representative patients (various primary disorders, highly comorbid, severe, referred by 
health practitioners), therapists (broad caseload, various levels of experience), and services 
(naturalistic community mental health clinic, Stewart & Chambless, 2009). To optimize the 
feasibility of running group therapy within community clinics, the treatment protocol in this 
study was shorter than in previous group and individual MCT trials. The shorter duration was 
expected to minimize attrition rates and clinician time per patient, which are important 
considerations within public mental health services where resources are scarce. 
The first hypothesis was that brief MCT would be acceptable to patients with primary 
or non-primary GAD in a community clinic, as evidenced by low attrition. The second 
hypothesis was that group MCT would be associated with significant reductions in positive 
and negative metacognitive beliefs, as well as diagnosis-specific (i.e., worry, rumination) and 
transdiagnostic measures of RNT. The frequency of specific negative automatic thoughts was 
also expected to reduce as a side effect of targeting metacognitive beliefs. The third 
hypothesis was that MCT would result in significant improvements in symptoms of anxiety, 
depression, general psychological distress, higher order psychological dimensions of positive 
and negative affect, and quality of life. The fourth hypothesis was that brief group MCT 
would compare favorably to previous treatment trials of primary GAD. 
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Method 
2.1 Participants 
Patients were referred by general practitioners, psychiatrists, or clinical psychologists 
to a specialist Australian community mental health clinic for psychological treatment of 
anxiety disorders and/or depression. A structured diagnostic interview (Mini International 
Diagnostic Interview, Lecrubier et al., 1997; Sheehan et al., 1998) was used to establish the 
presence of anxiety and/or depressive disorders. Primary diagnoses were those that patients 
nominated as most debilitating at the time of assessment. Patients were offered a place in the 
MCT group if they met criteria for GAD, with the exception of patients with primary social 
anxiety disorder (SAD) who were referred to a SAD-specific group. Patient flow is illustrated 
in Figure 1. Data were collected from 11 consecutive groups conducted between September 
2010 and July 2013, with between 3 and 7 patients per group (Median = 5). Only patients 
providing informed written consent for their clinical data to be used for research purposes 
were included in the analyses. 
Demographic information for patients attending at least one treatment session is 
summarized in Table 1. The duration of the current mental disorder episode exceeded a year 
for most of the sample (n = 39, 75%), with a median duration of three years. A significant 
minority of the sample had self-harmed, attempted suicide, or spent time as an inpatient at a 
psychiatric hospital. About two-thirds of patients were taking psychiatric medication (N = 35, 
67%) for an extended period of time (median 1 year; interquartile range 6 months to 4 years) 
without responding adequately. During the trial, one patient increased the dosage of her 
medication and another patient switched to a new medication. 
2.2 Outcome Measures 
2.2.1 Repetitive Negative Thinking. Three measures of RNT were administered; the 
Penn State Worry Questionnaire (PSWQ), the Ruminative Responses Scale (RRS), and the 
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Repetitive Thinking Questionnaire (RTQ-10). The PSWQ (Meyers, Miller, Metzger, & 
Borkovec, 1990) is a 16-item trait measure of pathological worry often used as the primary 
symptom measure in GAD treatment studies, while the RRS assesses the tendency to 
ruminate when feeling sad, blue or depressed. We used the five item brooding (RRS-BRO) 
and reflection (RRS-REF) subscales (Treynor, Gonzalez, & Nolen-Hoeksema, 2003). The 
RTQ-10 (Mahoney, McEvoy, & Moulds, 2012; McEvoy, Mahoney, & Moulds, 2010) is a 
transdiagnostic measure of RNT that has a robust unidimensional structure, distinguishes 
between clinical and non-clinical populations, and correlates very highly (r = .95) with the 
full 27-item scale (McEvoy et al., 2010; McEvoy, Thibodeau, & Asmundson, 2014). RTQ-10 
(henceforth the RTQ) total scores can fall between 10 and 50. Scores on the other RNT scales 
can range from 16 to 80 (PSWQ) and 5 to 20 (RRS-BRO and RRS-REF). In this study 
Cronbach’s alphas were high for all RNT measures (αs=.73-.95). 
2.2.2 Cognitions and Metacognitions. The frequency of depressive (14 items, CCL-
DEP) and anxious (12 items, CCL-ANX) thoughts was assessed using the Cognitions 
Checklist (Beck, Brown, Steer, Eidelson, & Riskind, 1987). Total scores fall between 0 and 
56 (CCL-DEP), or 0 to 48 (CCL-ANX). Metacognitions were assessed using the positive 
(MCQ-POS) and negative (MCQ-NEG) subscales from the Metacognitions Questionnaire-30 
(Wells & Cartwright-Hatton, 2004). The MCQ-POS is a measure of positive beliefs about 
worry, while the MCQ-NEG measures negative beliefs about the uncontrollability and 
dangerousness of worry. Both scales comprise 6 items, and scores can range between 6 and 
30. In this study Cronbach’s alphas were high for all CCL and MCQ subscales (αs=.73-.96).  
2.2.3 Symptoms and Quality of Life.  Psychiatric symptoms and wellbeing were 
assessed with widely used measures of psychological distress, affect, depression, anxiety, and 
quality of life. Psychological distress was measured using the Kessler Psychological Distress 
Scale-10 (K10, Kessler et al., 2002), and negative and positive affect using the Positive and 
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Negative Affect Schedule (PANAS; Watson, Clark, & Tellegen, 1988). Both measures have 
been widely used in previous transdiagnostic treatment trials (e.g., Farchione et al., 2012; 
Newby et al., 2013). The K10 consists of 10 items that measure common depressive and 
anxiety symptoms. The PANAS features 10-item positive (PANAS-POS) and negative 
(PANAS-NEG) affect subscales. Total scores for the K10, PANAS-POS and PANAS-NEG 
range from 10 and 50. The Beck Depression Inventory (BDI-II; Beck, Steer, & Brown, 1996) 
and Beck Anxiety Inventory (BAI; Beck, Epstein, Brown, & Steer, 1988) assessed depression 
and anxiety symptoms, respectively. Both comprise 21 items and total scores can range from 
0 to 63. The Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-
Q-SF; Endicott, Nee, Harrison, & Blumenthal, 1993) contains 14 items used to compute a 
total score, which is converted to a percentage (0%-100%). Cronbach’s alphas for all 
symptom and quality of life measures were high (αs=.85-.94). 
2.3 Procedure 
Patients referred for treatment were posted the questionnaire battery to complete and 
bring to their initial assessment, at which the MINI was completed by a Clinical Psychologist 
experienced in both the assessment and treatment of emotional disorders. In addition, all 
cases were presented at weekly clinic meetings where diagnoses and treatment plans were 
discussed. All measures were completed prior to the first session, and following session 6 
(post-treatment) and session 7 (follow-up). This study was approved by the Health Service’s 
Human Research Ethics Committee (Reference # QI 2014_04). 
2.4 Treatment 
The group MCT program (Anderson & Campbell, 2011, manual available from first 
author) aimed to challenge positive and negative metacognitive beliefs about RNT (Wells, 
2009), increase attentional flexibility, and improve active coping skills across six two-hour 
sessions (Sessions 1-6) plus a one-month follow-up (Session 7). Treatment fidelity was 
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supported by the use of a treatment manual that included detailed therapist notes, worksheets, 
and client handouts. Senior therapists had completed masters and/or doctoral degrees in 
clinical psychology and received weekly peer supervision. All groups were co-facilitated by 
one (7 groups) or two senior therapists (1 group), or one senior therapist plus one trainee 
therapist completing a masters or doctorate in clinical psychology (3 groups). All senior 
therapists had extensive experience at facilitating group interventions, with most participating 
in previous treatment effectiveness studies. 
Session 1 covered psychoeducation about the nature of worry and rumination (RNT) 
and maintaining factors including negative beliefs about RNT (dangerousness, 
uncontrollability), unhelpful behaviors aiming to stop RNT (e.g., situational avoidance, 
thought suppression, reassurance, information-seeking, use of alcohol and drugs), attentional 
biases (e.g., past-, future-, and self-focused attention vs. task-focused attention), and positive 
beliefs about RNT (beliefs about how RNT could be helpful). Homework included 
monitoring RNT and associated symptoms and strategies typically used to control RNT. 
Session two began with a homework review, whereas the remaining sessions began 
with an attention training exercise (i.e., mindfulness) followed by a homework review, before 
discussing the new content and finally setting homework for the following week. Session 2 
targeted uncontrollability metacognitions and attention training. The belief that RNT is 
uncontrollable was first challenged using evidence testing with the whole group and then by 
setting a RNT postponement experiment for homework with a scheduled daily worry time. 
Attention training was introduced to increase internally- and externally-focused attentional 
flexibility, and included mundane task focusing (i.e., sustaining attention on present moment 
activity) and mindfulness (e.g., watching thoughts drift by, mindfulness of the breath). The 
rationale for these exercises was that regular practice facilitates attentional awareness, 
detachment, and redirection to a present task focus. It is noteworthy that this approach to 
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attention training differs from Wells’ (2009) attention training technique, which is designed 
to increase attentional flexibility and direct attention away from the self. Session 3 focused 
on identifying and challenging dangerousness metacognitions. Group evidence-testing was 
completed to challenge beliefs that RNT is harmful, and behavioral experiments were 
collaboratively set for homework to challenge each patient’s idiosyncratic dangerousness 
metacognitions. For instance, RNT up and down experiments were planned during which 
patients were encouraged to test their negative metacognitions by, on alternate days, either 
fully engaging in RNT or postponing RNT whilst monitoring outcomes with respect to their 
predictions. Patients were also taught questions that could help them to determine the veracity 
of the information they gathered with respect to their negative beliefs about RNT (e.g., Was it 
written by a qualified professional? Does the author represent an established and reputable 
health organization? Is the author free of commercial interests? Does the article include 
multiple pieces of evidence to back up its claims?). 
Session 4 focused on challenging positive metacognitions in the group, first by group 
evidence-testing and then by setting a RNT up and down experiment for homework. In 
Session 5 patients were encouraged to rely on ‘postponement’ strategies for managing 
repetitive negative thoughts, which is consistent with MCT. In addition, active coping 
(structured problem-solving) was introduced as a technique to be used in worry time for 
constructively managing solvable problems that require action. Whilst active coping is a 
departure from Wells’ (2009) MCT it was used to discourage maladaptive behavioral 
responses that constitute part of the Cognitive Affective Syndrome (e.g., repetitive checking, 
avoidance). Session 6 involved a review of the key principles and development of self-
management plans, including early warning signs for RNT, potential risky situations, 
strategies/techniques that could be used to prevent a setback, and coping statements that 
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could be used to interrupt RNT. The follow-up session involved a review of progress and 
self-management plans. 
2.5 Data Analyses 
The first hypothesis was evaluated by reporting attendance rates. The second and third 
hypotheses were evaluated by examining the magnitude of effect sizes. Standardized effect 
sizes (Cohen’s d; Cumming 2012) were computed using the formula d = (M1 – M2)/ SDpre, 
where M1 and M2 are means at two time points (such as pre- and post-treatment, or pre-
treatment and follow-up) and SDpre is the pre-treatment standard deviation. Desirable 
changes, such as a reduction in depression or an increase in quality of life, resulted in a 
positive d value. Reliable and clinically significant change indices were calculated for the 
PSWQ (Jacobson & Truax, 1991).  
The fourth hypothesis was evaluated by benchmarking the PSWQ outcomes in the 
current study against those of RCTs that investigated the efficacy or effectiveness of 
psychological interventions for primary GAD. To ensure that the results were comparable to 
the RCTs, these analyses used the subset of patients with primary GAD (n = 40) rather than 
the whole sample (n = 52). Trials from a recent meta-analysis (Hanrahan, Field, Jones, & 
Davey, 2013) and literature searches were used as benchmarks if (a) patients were diagnosed 
with primary GAD, (b) the PSWQ was used as an outcome measure, (c) patients were treated 
with a face-to-face psychological intervention, (d) intent-to-treat analyses were reported, and 
(e) at least 20 patients received treatment. 
All analyses were intent-to-treat (ITT) and were conducted using the statistical 
software R version 3.0.1 (R Core Team, 2013). Missing data were handled using multiple 
imputation (National Research Council Panel on Handling Missing Data in Clinical Trials, 
2010). One hundred imputations were generated using the robust model based imputation 
algorithm (Templ, Kowarik, & Filzmoser, 2011) implemented in the R package VIM (Templ, 
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Alfons, Kowarik, & Prantner, 2013). Analyses performed on each imputed dataset were 
pooled using standard multiple imputation rules (van Buuren, 2012). 
Results 
3.1 Session Attendance 
 Most patients attended at least five treatment sessions (N = 46, 88%), and all except 
one attended at least four. The one month follow-up was attended by 37 patients (71%). 
3.2 Mean Changes and Standardized Effect Sizes 
Mean scores at pre-treatment, post-treatment and follow-up are reported in Tables 2 
and 3. There were statistically significant improvements on all 14 measures between pre-and 
post-treatment (all ps < .001). Effect sizes (unstandardized and standardized) and confidence 
intervals are also reported in Tables 2 and 3. The standardized effect sizes are plotted in 
Figure 2. The dotted vertical lines correspond to what are typically regarded as small (d = .2), 
medium (d = .5) and large (d = .8) effects (Cumming, 2012). Effect sizes were extremely 
large on the measures of negative metacognitions, worry, and RNT. There were also medium 
to very large effects observed on the other measures. Effect sizes for most measures increased 
between post-treatment and follow up. The effect sizes for negative metacognitions, worry 
and RNT were very large at follow up, exceeding two standard deviations. 
3.3 Clinical Significance 
Using Jacobson and Truax’s (1991) method, a reliable change index (RCI) of 7 plus a 
score of ≤ 59 were used to define recovery. If a patient’s score on the PSWQ declined by at 
least 7 points they were classed as having reliably improved; if their score increased by 7 or 
more points they were regarded as having reliably deteriorated. If a patient’s score improved 
by at least 7 points and they had a score on the PSWQ at post-treatment (or follow-up) of 59 
or less, they were classed as having recovered. We used a cutoff of 59 as recently published 
community and clinical norms indicate that a score of 58 or 59 is the boundary that best 
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differentiates normal and pathological worry (van der Heiden, Muris, Bos, Molen, & Oostra, 
2009). No patients fell below this clinical cutoff at pre-treatment. At post-treatment no 
patients had reliably deteriorated, 86% had reliably improved, CI [77%, 96%], p < .001, and 
74% had recovered, CI [62%, 86%], p <.001. The percentages were the same at follow up. 
When a lower PSWQ cutoff of 53 was used, which has been applied in some recent studies, 
85% and 90% achieved reliable improvement at post-treatment and follow-up, respectively, 
and 65% recovered at both post-treatment and follow-up. These proportions compared well to 
van der Heiden et al.’s (2012) and van der Heiden et al.’s (2013) individual and group MCT 
outcomes, who used the same criterion (60-77% reliably improved, 37%-63% recovered). 
3.4 Benchmarking PSWQ scores against RCTs 
 PSWQ outcomes were benchmarked against eight RCTs for primary GAD (Figure 3). 
Comparison individual treatments (N = 14) involved 12 to 30 therapy/therapist hours per 
patient. There were two comparison group treatments. Van der Heiden et al.’s (2012) groups 
included 10-14 patients over 14, 90-minute sessions, resulting in an average of 1.91 therapy 
hours/patient and 3.82 therapist hours/patient (14 sessions x 1.5 hours = 21 hours, 3 groups = 
total of 63 therapy hours, a total sample of 33 = 63/33 = 1.91 hours per patient; 2 
therapists/group = 3.82 therapist hours/patient). Using similar calculations, Dugas et al.’s 
(2003) groups included used an average of 5.6 therapy hours/patient and 11.2 therapist 
hours/patient. The group treatment in this study included a combination of single therapist 
and co-therapist groups, typically to allow unpaid trainees to participate as co-therapists to 
meet their learning objectives at no cost to the service. Including these trainees as co-
therapists translates to 2.96 therapy hours/patient and 3.96 therapist hours/patient. Therefore, 
the treatment in this study required similar therapist hours per patient to van der Heiden et 
al.’s (2012) group treatment but substantially less than the other comparison treatments. 
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Figure 2 contains a plot of pre- to post-treatment mean change scores for each study.  
These have been converted into standard deviation units (d) by dividing each change score by 
7.93, which was the pre-treatment pooled standard deviation across all studies. The circles are 
the effect sizes for the comparison treatments. The triangle is the pre- to post-treatment effect 
size in the current study, and the square is the change from pre-treatment to follow-up in the 
current study, which at 10 weeks was shorter than the period between pre- and post-treatment 
assessments in all of the RCTs. Effect sizes in the current study were numerically larger than 
those observed in most of the RCTs. A control group effect size was calculated by pooling 
the pre- and post-treatment means across all waitlist groups (5 groups, 95 patients) from the 
benchmarking studies. Mean PSWQ total scores increased by .025 points (d = .03) during the 
waitlist period (12-14 weeks), suggesting that scores were stable without treatment. 
Discussion 
The main aim of this study was to evaluate a brief, six-session (plus 1 month follow-
up) MCT protocol in individuals with primary or non-primary GAD. It was hypothesized that 
group MCT would be acceptable to patients, and would be associated with significant 
reductions in positive and negative metacognitive beliefs, RNT, anxious and depressive 
thoughts, positive and negative affect, and improved quality of life. It was also expected that 
these outcomes would compare favorably to previous trials of MCT for primary GAD. These 
hypotheses were supported. 
Most patients attended 5 or 6 sessions of the six-session program, suggesting that they 
found MCT an acceptable way of targeting their RNT. MCT was associated with significant 
reductions in both positive and negative metacognitive beliefs, although the reductions were 
considerably larger for negative (uncontrollability and dangerousness) than positive 
metacognitions. It is notable that at pre-treatment patients endorsed fewer positive 
metacognitive beliefs, resulting in a floor effect, compared to negative metacognitive beliefs. 
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This pattern is consistent with therapists’ observations that many patients deny benefits of 
their RNT at pre-treatment, and only acknowledge positive metacognitions later in treatment. 
Once patients have thoroughly tested the uncontrollability and dangerousness beliefs in early 
sessions, and no longer believe that their RNT is uncontrollable, many acknowledge that they 
choose to continue worrying on some occasions due to a range of perceived benefits (e.g., 
helps to keep me prepared, might prevent bad things happening, it is part of my identity). 
Positive beliefs may therefore be more strongly endorsed at mid-treatment, compared to the 
initial assessment when patients are more focused on the distress caused by their RNT. The 
fact that negative beliefs are targeted earlier in the program may also explain the larger effect 
sizes compared to positive beliefs. Our clinical impression is that positive beliefs are more 
easily acknowledged, challenged, and modified after negative beliefs have already been 
addressed, and that modifying these beliefs is important for reducing vulnerability to relapse. 
However, we were unable to demonstrate this in the current study as metacognitive beliefs 
were not assessed at each treatment session. 
Engagement in RNT significantly and substantially reduced during treatment, with 
very large effect sizes on the RTQ and PSWQ, and large effect sizes on the RRS-Brooding 
subscale. This finding suggests that MCT has a large impact on diagnosis-specific (i.e., worry 
and rumination) and transdiagnostic measures of RNT. Although the psychometric properties 
of the RTQ are now well established (Mahoney et al., 2012; McEvoy et al., 2010; McEvoy et 
al., 2014), this is the first treatment study to compare the sensitivity to change of the RTQ as 
a measure of transdiagnostic RNT to diagnosis-specific measures. Our findings suggest that it 
was equally sensitive to change as the PSWQ and more so than the RRS subscales. The 
magnitude of these changes is striking given that the treatment was relatively brief, delivered 
within a group format, and included patients with primary and non-primary GAD. 
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 Interestingly, the frequency of specific depressive and anxious negative thoughts also 
reduced during treatment despite the fact that negative automatic thoughts were not directly 
addressed during the protocol. This finding suggests that the frequency of negative thoughts 
reduced as a side effect of targeting metacognitive beliefs and, as such, the content of specific 
negative thoughts may not need to be directly addressed. Once individuals are equipped to 
disengage from the process of RNT then the content of specific negative thoughts appears to 
naturally intrude less frequently. 
Although most studies of MCT have used very small samples, two exceptions are van 
der Heiden et al. (2012, N = 61) and van der Heiden et al. (2013, N = 33), who evaluated 
individual and group MCT, respectively. These authors found that 14 sessions of MCT 
effectively reduced worry for patients with primary GAD. van der Heiden et al. (2013) found 
smaller effect sizes for their group treatment than for the same treatment offered individually 
by van der Heiden et al. (2012). Benchmarking comparisons found that the brief, 6-week 
MCT group program evaluated in this study was associated with substantially larger changes 
in worry than van der Heiden et al.’s (2013) group treatment, which required a similar 
number of therapist hours per patient. These superior group outcomes may be explained, at 
least in part, by the use of smaller groups (3-7/group vs. 10-14/group), which may enable 
more individualized therapist attention to idiosyncratic beliefs and obstacles to change. 
The effect sizes from this study were slightly smaller than van der Heiden et al.’s 
(2012) individual treatment. It is notable that the final assessment in this study was completed 
10-weeks after treatment commencement, rather than at 14 weeks in van der Heiden et al.’s 
(2012) study. If the trajectory of improvement between post-treatment and follow-up 
continued then effect sizes from this study would have been comparable to van der Heiden et 
al.’s (2012) individual treatment outcomes by week 14. Interestingly, the post-treatment 
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PSWQ standard deviation in this study (SD = 6.9) was less than half that reported by van der 
Heiden et al. (2012, SD = 15.8), suggesting a more consistent treatment effect in group MCT. 
Ladouceur et al. (2000) evaluated a 16-week Intolerance of Uncertainty Therapy 
(IUT) protocol in a relatively small sample (N = 26) with primary GAD based on the 
Intolerance of Uncertainty Model. These researchers found a slightly larger effect size than 
ours at follow-up and, again, outcomes may be comparable 16-weeks after commencement of 
our brief MCT protocol. Importantly, four subsequent trials of IUT failed to replicate the 
magnitude of Ladouceur et al.’s (2000) effects and, although they still found IUT to be 
effective, the effect sizes were smaller than for the brief group MCT protocol evaluated in 
this study (Dugas et al., 2003; Dugas et al., 2010; Gosselin, 2006; van der Heiden et al., 
2012). Newman et al.’s (2011) evaluation of an integrated, 14-session CBT and interpersonal 
plus emotional processing therapy also resulted in comparable effect sizes to our study. 
Targeting transdiagnostic metacognitions, rather than the content of diagnosis-specific 
cognitions, means that this approach is amenable to including diagnostically diverse samples. 
The findings of this study suggest that including a subsample with non-primary GAD did not 
adversely affect change in the primary therapeutic targets, which is important because many 
community clinics may not receive enough referrals to run groups based on primary 
disorders. Transdiagnostic group treatments may be an effective, efficient, and pragmatic way 
of offering treatment to a broader array of individuals. The brevity of the MCT program 
evaluated in this study makes it easier for therapists to schedule, and may help to minimize 
attrition without compromising the magnitude of change, compared to longer programs.  
This study has several limitations that need to be considered. Firstly, the absence of a 
control group means that we could not rule out the possibility that factors other than MCT 
contributed to outcomes (e.g., non-specifics of therapy, medication, time). However, these 
factors are unlikely to fully account for the outcomes due to the long duration of medication 
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use (median = 2 years), the chronicity of self-reported RNT, and the benchmarking 
comparisons demonstrating comparable or superior outcomes to active treatments in RCTs 
and superior outcomes to waitlist controls. Secondly, sessions were not recorded to evaluate 
protocol adherence and therapist competence, and diagnoses were not confirm by a second 
assessor. While these limitations suggest that some caution is required when interpreting 
these results, they are typical of real world clinical practice and the findings nonetheless 
contribute to the limited existing knowledge about the potential benefits of using MCT in 
clinical samples referred to community clinics. Future RCTs evaluating MCT, mechanisms of 
change, including longer term follow-ups, and with other primary emotional disorders would 
be valuable for ensuring that these findings are replicable, enduring, and generalizable to 
other samples and settings. 
This study is the first to evaluate the effectiveness of group MCT for a sample with 
primary or non-primary GAD in a community mental health clinic. Group MCT had low 
attrition and was associated with significant and substantial improvements in RNT, 
metacognitions, higher-order dimensions of positive and negative affect, symptoms, and 
quality of life. The relatively brief MCT protocol evaluated in this study resulted in 
comparable changes to substantially longer group and individual treatments. Transdiagnostic 
MCT appears to be an acceptable, effective, efficient, and practical intervention for targeting 
RNT in emotional disorders. 
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 Mean age (SD) 38.0 (14.3) 
Female 60 
Employed 63 
  Education 
 University 52 
Technical or Trade Certificate 23 
High School or less 25 
  Relationship Status 
 Married / Defacto 52 
Single 40 
Other 8 
  Number of Diagnoses 
 1 37 
2 44 
3 or more 19 
  Primary Diagnosis 
 Generalized Anxiety Disorder 77 
Major Depressive Disorder 17 
Other 6 
  Primary, Secondary or Tertiary Diagnosis 
 Generalized Anxiety Disorder 100 
Major Depressive Disorder 35 
Social Phobia 21 
Other 32 
  Other Clinical Features 
 Taking Psychotropic Medication 67 
Previous Psychiatric Hospitalization 25 
Attempted Suicide or Self-Harmed 15 
Note. Other than age, all other values are percentages. 
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 Table 2. 
Measures of Metacognition, Repetitive Negative Thinking, and Negative Automatic Thoughts 
Measure and Timepoint 
      
Mean Change 
from Pre-treatment   
Standardized 
Mean Change (d ) 
M SD   Est 95% CI   Est 95% CI 
            Negative Metacognitions (MCQ-NEG) 
 
Pre 17.93 3.65 
        
 
Post 10.99 3.94 
 
6.94 5.80 8.07 
 
1.90 1.35 2.45 
 
Follow Up 9.63 4.23 
 
8.30 7.05 9.54 
 
2.27 1.68 2.86 
            Positive Metacognitions (MCQ-POS) 
 
Pre 12.13 4.63 
        
 
Post 9.63 3.83 
 
2.50 1.19 3.81 
 
.54 .26 .82 
 
Follow Up 8.39 3.11 
 
3.74 2.51 4.97 
 
.81 .53 1.08 
            Repetitive Thinking (RTQ) 
 
Pre 40.36 7.01 
        
 
Post 28.10 8.31 
 
12.26 9.93 14.59 
 
1.75 1.20 2.30 
 
Follow Up 24.83 8.26 
 
15.53 13.40 17.66 
 
2.22 1.63 2.81 
            Worry (PSWQ) 
 
Pre 66.14 8.07 
        
 
Post 51.49 9.00 
 
14.65 12.28 17.02 
 
1.82 1.34 2.29 
 
Follow Up 48.50 9.25 
 
17.64 15.16 20.13 
 
2.19 1.66 2.71 
            Brooding Rumination (RRS-B) 
 
Pre 13.06 3.40 
        
 
Post 10.27 2.92 
 
2.79 1.98 3.60 
 
.82 .53 1.11 
 
Follow Up 9.44 2.32 
 
3.61 2.73 4.49 
 
1.06 .79 1.34 
            Reflective Rumination (RRS-R) 
 
Pre 11.25 3.85 
        
 
Post 9.34 2.59 
 
1.90 0.98 2.83 
 
.49 .25 0.74 
 
Follow Up 9.63 3.12 
 
1.62 0.63 2.61 
 
.42 .16 0.68 
            Depressive Cognitions (CCL-D) 
 
Pre 23.47 9.67 
        
 
Post 15.78 10.31 
 
7.69 5.39 9.99 
 
.80 .48 1.11 
 
Follow Up 11.64 9.00 
 
11.84 9.59 14.08 
 
1.22 .89 1.56 
            Anxious Cognitions (CCL-A) 
 
Pre 15.50 8.94 
        
 
Post 10.76 8.58 
 
4.74 2.99 6.50 
 
.53 .30 .76 
  Follow Up 8.91 7.64   6.59 4.72 8.45   .74 .50 .97 
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Table 3. 
Symptom Measures 
Measure and Timepoint 
      
Mean Change 
from Pre-treatment   
Standardized 
Mean Change (d ) 
M SD   Est 95% CI   d 95% CI 
            Psychological Distress (K10) 
 
Pre 27.42 7.21 
        
 
Post 21.16 6.97 
 
6.26 4.91 7.62 
 
.87 .64 1.09 
 
Follow Up 20.08 6.92 
 
7.34 5.75 8.93 
 
1.02 .75 1.28 
            Depression (BDI-II) 
 
Pre 23.04 11.50 
        
 
Post 13.10 9.68 
 
9.94 7.42 12.45 
 
.86 .58 1.15 
 
Follow Up 11.73 8.63 
 
11.31 8.62 14.00 
 
.98 .69 1.28 
            Anxiety (BAI) 
 
Pre 17.52 11.42 
        
 
Post 10.90 7.00 
 
6.62 4.28 8.96 
 
.58 .40 .76 
 
Follow Up 10.02 7.90 
 
7.49 4.76 10.23 
 
.66 .43 .88 
            Negative Affect (PANAS-NEG) 
 
Pre 28.49 7.22 
        
 
Post 20.58 6.99 
 
7.91 6.00 9.82 
 
1.10 .74 1.45 
 
Follow Up 19.57 7.05 
 
8.93 7.14 10.71 
 
1.24 .86 1.61 
            Positive Affect (PANAS-POS) 
 
Pre 25.47 7.25 
        
 
Post 29.24 6.57 
 
3.77 2.29 5.25 
 
.52 .30 .74 
 
Follow Up 30.27 7.80 
 
4.80 2.86 6.74 
 
.66 .39 .93 
            Quality of Life (QLESQ-SF) 
 
Pre 50.67 14.92 
        
 
Post 58.42 15.73 
 
7.75 4.69 10.81 
 
.52 .28 .76 
  Follow Up 61.41 17.14   10.74 6.86 14.62   .72 .42 1.02 
 
Note. Est = point estimate of the (standardized) mean difference.  95% CI = 95 percent 
confidence interval. 
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N = 70 
Allocated to Treatment 
N = 55 
Excluded 
N = 15 
Consent to use data for research declined (n=7) 
Preferred individual treatment (n=5) 
No GAD diagnosis (n=3) 
 
Attended ≥1 session 
N = 52 Did not attend any sessions 
N = 3 
Unexplained dropout 
Attended session 6 
(i.e., has post data) 
N = 46 
Attended follow-up 
N = 37 
Discontinued 
N = 6 
Physical Illness (n=2) 
Patient unhappy with treatment after 2 sessions (n=1) 
Unexplained dropout (n=3) 
Unexplained dropout (1) 
Did not attend follow-up 
N = 9 
Forgot date of session (n=3) 
Clashed with child’s medical appointment (n=1) 
Moved away (n=1) 
Unexplained dropout (n=4) 
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Figure 3. Benchmarking Plots of Penn State Worry Questionnaire Standardized Mean Differences 
 
Note.  Trtmt = Treatment type, Sess = Number of Sessions, Wks = Number of weeks between pre and post-treatment assessments, d = 
Standardized Mean Change Score, Grp = Group treatment, Ind = Individual treatment, AR = Applied Relaxation,  CBT = Cognitive 
Behavior Therapy based on Borkovec’s avoidance model, CBT+SC = CBT plus Supportive Counseling, CBT+IEP = CBT plus 
Integrated techniques from Emotion-focused and Interpersonal therapies, CBT+MED = CBT plus antidepressant medication, IUT = 
CBT based on an Intolerance of Uncertainty model, ABBT = Acceptance-Based Behaviour Therapy (ABBT), MCT = Metacognitive 
Therapy for GAD, MCT-T = Transdiagnostic Metacognitive Therapy.  
 
